国产与进口多西他赛辅助治疗Ⅲ-Ⅳ期非小细胞肺癌的成本-效果比较

Comparative Analysis of Cost-effectiveness of Domestic and Imported Docetaxel in Adjuvant Treatment of Patients with Stage Ⅲ-Ⅳ Non-small Cell Lung Cancer

目的:比较国产与进口多西他赛辅助治疗Ⅲ-Ⅳ期非小细胞肺癌(NSCLC)的成本-效果。方法:选取2017年4月—2019年10月本院收治的Ⅲ-Ⅳ期NSCLC患者92例,简单随机化分为国产组和进口组各46例。两组治疗均采用多西他赛+顺铂方案,进口组采用进口多西他赛,国产组采用国产多西他赛。比较两组治疗2个周期后的疗效、肿瘤标志物[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、微小RNA-23a(miR-23a)、微小RNA-451(miR-451)]、成本-效果、不良反应等。结果:国产组缓解率为21.74%,与进口组的26.09%比较,差异无统计学意义(P>0.05);治疗后组间NSE、CEA、miR-23a、miR-451比较,差异无统计学意义(P>0.05);国产组取得每个单位效果成本为237.48元,进口组取得每个单位效果成本为441.72元,且每增加一个单位效果,比国产组多付出1462.46元;两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论:国产与进口多西他赛辅助治疗Ⅲ-Ⅳ期NSCLC的疗效和安全性相似,但国产多西他赛在成本-效果方面具有应用优势。

Objective:To compare the cost-effectiveness of domestic and imported docetaxel in adjuvant treatment of stageⅢ-Ⅳnon-small cell lung cancer(NSCLC).Methods:From April 2017 to October 2019,92 patients with stage III-IV NSCLC admitted to our hospital were selected and divided into groups according to simple randomization,with 46 cases in each group.Both groups used the docetaxel+cisplatin solution,the imported group used imported docetaxel,and the domestic group used domestic docetaxel.The efficacy,tumor markers[carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),microRNA-23a(miR-23a),microRNA-451(miR-451)]after 2 cycles of treatment,cost-effectiveness,and adverse reactions were compared between the two groups.Results:The remission rate of the domestic group was 21.74%,compared with 26.09%of the imported group,the difference was not statistically significant(P>0.05).There was no statistically significant difference in NSE,CEA,miR-23a,miR-451 between groups after treatment(P>0.05).The cost of each unit effect obtained by the domestic group was 237.48 yuan,and the cost of each unit effect obtained by the imported group was 441.72 yuan.The imported group was higher than the domestic group,and each additional unit of effect paid 1462.46 yuan more than the domestic group.There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy and safety of domestic and imported docetaxel in adjuvant treatment of stage III-IV NSCLC are similar,but domestic docetaxel has an application advantage in terms of cost-effectiveness.